BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23699658)

  • 1. Discovery of new small molecules targeting the vitronectin-binding site of the urokinase receptor that block cancer cell invasion.
    Rea VE; Lavecchia A; Di Giovanni C; Rossi FW; Gorrasi A; Pesapane A; de Paulis A; Ragno P; Montuori N
    Mol Cancer Ther; 2013 Aug; 12(8):1402-16. PubMed ID: 23699658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.
    Liu D; Zhou D; Wang B; Knabe WE; Meroueh SO
    ACS Chem Biol; 2015 Jun; 10(6):1521-34. PubMed ID: 25671694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The urokinase receptor takes control of cell migration by recruiting integrins and FPR1 on the cell surface.
    Gorrasi A; Li Santi A; Amodio G; Alfano D; Remondelli P; Montuori N; Ragno P
    PLoS One; 2014; 9(1):e86352. PubMed ID: 24466048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting multiple conformations leads to small molecule inhibitors of the uPAR·uPA protein-protein interaction that block cancer cell invasion.
    Khanna M; Wang F; Jo I; Knabe WE; Wilson SM; Li L; Bum-Erdene K; Li J; W Sledge G; Khanna R; Meroueh SO
    ACS Chem Biol; 2011 Nov; 6(11):1232-43. PubMed ID: 21875078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stabilizing a flexible interdomain hinge region harboring the SMB binding site drives uPAR into its closed conformation.
    Zhao B; Gandhi S; Yuan C; Luo Z; Li R; Gårdsvoll H; de Lorenzi V; Sidenius N; Huang M; Ploug M
    J Mol Biol; 2015 Mar; 427(6 Pt B):1389-1403. PubMed ID: 25659907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors.
    Mauro CD; Pesapane A; Formisano L; Rosa R; D'Amato V; Ciciola P; Servetto A; Marciano R; Orsini RC; Monteleone F; Zambrano N; Fontanini G; Servadio A; Pignataro G; Grumetto L; Lavecchia A; Bruzzese D; Iaccarino A; Troncone G; Veneziani BM; Montuori N; Placido S; Bianco R
    Sci Rep; 2017 Aug; 7(1):9388. PubMed ID: 28839232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A composite role of vitronectin and urokinase in the modulation of cell morphology upon expression of the urokinase receptor.
    Hillig T; Engelholm LH; Ingvarsen S; Madsen DH; Gårdsvoll H; Larsen JK; Ploug M; Danø K; Kjøller L; Behrendt N
    J Biol Chem; 2008 May; 283(22):15217-23. PubMed ID: 18362146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-based therapy.
    Lund IK; Illemann M; Thurison T; Christensen IJ; Høyer-Hansen G
    Curr Drug Targets; 2011 Nov; 12(12):1744-60. PubMed ID: 21707477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region.
    Gårdsvoll H; Ploug M
    J Biol Chem; 2007 May; 282(18):13561-72. PubMed ID: 17355965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration.
    Duriseti S; Goetz DH; Hostetter DR; LeBeau AM; Wei Y; Craik CS
    J Biol Chem; 2010 Aug; 285(35):26878-26888. PubMed ID: 20501655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single amino acid substitutions in the chemotactic sequence of urokinase receptor modulate cell migration and invasion.
    Bifulco K; Longanesi-Cattani I; Franco P; Pavone V; Mugione P; Di Carluccio G; Masucci MT; Arra C; Pirozzi G; Stoppelli MP; Carriero MV
    PLoS One; 2012; 7(9):e44806. PubMed ID: 23049759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. uPAR regulates pericellular proteolysis through a mechanism involving integrins and fMLF-receptors.
    Montuori N; Cosimato V; Rinaldi L; Rea VE; Alfano D; Ragno P
    Thromb Haemost; 2013 Feb; 109(2):309-18. PubMed ID: 23238745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of new small molecules inhibiting 67 kDa laminin receptor interaction with laminin and cancer cell invasion.
    Pesapane A; Di Giovanni C; Rossi FW; Alfano D; Formisano L; Ragno P; Selleri C; Montuori N; Lavecchia A
    Oncotarget; 2015 Jul; 6(20):18116-33. PubMed ID: 26062445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A flexible multidomain structure drives the function of the urokinase-type plasminogen activator receptor (uPAR).
    Mertens HD; Kjaergaard M; Mysling S; Gårdsvoll H; Jørgensen TJ; Svergun DI; Ploug M
    J Biol Chem; 2012 Oct; 287(41):34304-15. PubMed ID: 22896701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urokinase type plasminogen activator receptor (uPAR) as a new therapeutic target in cancer.
    Montuori N; Pesapane A; Rossi FW; Giudice V; De Paulis A; Selleri C; Ragno P
    Transl Med UniSa; 2016 Nov; 15():15-21. PubMed ID: 27896223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct evidence of the importance of vitronectin and its interaction with the urokinase receptor in tumor growth.
    Pirazzoli V; Ferraris GM; Sidenius N
    Blood; 2013 Mar; 121(12):2316-23. PubMed ID: 23327926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urokinase receptor-dependent upregulation of smooth muscle cell adhesion to vitronectin by urokinase.
    Chang AW; Kuo A; Barnathan ES; Okada SS
    Arterioscler Thromb Vasc Biol; 1998 Dec; 18(12):1855-60. PubMed ID: 9848876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conformational regulation of urokinase receptor function: impact of receptor occupancy and epitope-mapped monoclonal antibodies on lamellipodia induction.
    Gårdsvoll H; Jacobsen B; Kriegbaum MC; Behrendt N; Engelholm L; Østergaard S; Ploug M
    J Biol Chem; 2011 Sep; 286(38):33544-56. PubMed ID: 21799009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequences within domain II of the urokinase receptor critical for differential ligand recognition.
    Li Y; Lawrence DA; Zhang L
    J Biol Chem; 2003 Aug; 278(32):29925-32. PubMed ID: 12761227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The uPA receptor and the somatomedin B region of vitronectin direct the localization of uPA to focal adhesions in microvessel endothelial cells.
    Salasznyk RM; Zappala M; Zheng M; Yu L; Wilkins-Port C; McKeown-Longo PJ
    Matrix Biol; 2007 Jun; 26(5):359-70. PubMed ID: 17344041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.